Introduction {#Sec1}
============

In the recent past, carbapenems were potent against all multiple drug resistant (MDR) Gram negative bacteria and in combination with their negligible toxicity to the host, carbapenems became the preferred last resort antibiotics for the treatment of MDR Gram negative bacterial infections. Development of carbapenem resistance (CR) in *Enterobacteriaceae* is of great concern because there is no obvious next line of antibiotics to use against carbapenemase producing (CP) *Enterobacteriaceae* \[[@CR1]\]. MDR has left less efficient antibiotics to take care of these expensive hard to treat life threatening infections \[[@CR2]--[@CR6]\].

Currently, the high prevalence of carbapenem resistant *Enterobacteriaceae* (CRE) isolates world over most importantly in *Klebsiella pneumoniae* and *Escherichia coli* isolates in hospitals, community-associated infections and animals is a huge burden to the health care system \[[@CR3], [@CR5]--[@CR12]\], Additional file [2](#MOESM2){ref-type="media"}: Table S6. Genetic determinants of CR have been classified into: Ambler class A beta lactamases which include; KPC, GES/IBC, SME, NMC-A, IMI and SFC \[[@CR12]--[@CR15]\], Ambler class B beta lactamases which are termed as Metallo beta Lactamases consisting of NDM, VIM, IMP, SPM, GIM, SIM, KHM, AIM, DIM, SMB, TMB and FIM \[[@CR7], [@CR13]\]. IMP, VIM and NDM plasmid mediated Metallo beta lactamases are of worldwide occurrence possibly because the genes that code for them are located on mobile genetic elements \[[@CR13]\] and carbapenem hydrolyzing class D beta lactamases (CHDLs) encompass various group of oxacillinases (OXA) with hydrolytic activity of amino and carboxy penicillins \[[@CR16]\], Additional file [2](#MOESM2){ref-type="media"}: Tables S3--S5.

Studies have reported the existence of CP bacteria in East Africa but in general, there is no comprehensive data about the molecular epidemiology of CP organisms and its burden on the health care system \[[@CR17], [@CR18]\]. Furthermore, there is scanty information about CR prevalence in East African livestock yet MDR genes were observed in livestock commensal bacteria which are probably transmitted to humans through the food chain \[[@CR19]--[@CR21]\].

Comprehending the current status of CR throughout East Africa will influence decision making among stakeholders about the rational use of carbapenems. Therefore, this systematic review expounds the current molecular epidemiology of CP bacteria in East Africa, highlighting the carbapenemases genes, CR Knowledge gap and future research interventions to address CR in East Africa.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Literature review {#Sec4}

PubMed, ScienceDirect and African Journals Online databases were searched from March to December 2017. The search key words used were carbapenem resistance in East Africa to extract articles published only in English from 2008 onwards in an attempt to include up to date relevant CR data, Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Selection process of research articles for inclusion in this systematic review

### Study selection criteria {#Sec5}

Only full text research articles reporting the prevalence of CP bacteria isolated from patients and hospital environment in East African countries namely; Kenya, Uganda, Tanzania, Burundi, Rwanda, Ethiopia, Democratic Republic of Congo (DRC) and South Sudan were used. Only Studies elaborating bacteria study population, pathogens identified, phenotypic and genotypic methods used to detect CR were used. Patients' populations of all ages were included while case reports and review articles were excluded from this systematic review as it has become conventional \[[@CR22]\].

### Data extraction {#Sec6}

A database was created in which study location, publication year, sample collection period, bacterial species isolated, number of isolates tested for CR, CR prevalence, carbapenemase genes, methods used to identify resistant isolates and to type CR genetic determinants were included, Table [1](#Tab1){ref-type="table"}.Table 1Review of East Africa based carbapenem resistance studiesLocationNumber of isolatesCR isolatesCR prevalence (%)Carbapenemase genesOrganismPeriodMethods usedRefsKenya4165713.7VIM-2*P. aeruginosa*Jan 2006--Jun 2007PCR, PFGE and sequencing\[[@CR23]\]Kenya\> 1007--NDM-1*K. pneumoniae*2007--2009PCR, PFGE and sequencing\[[@CR24]\]Kenya--16--NDM-1*A. baumannii*Jan 2009--Aug 2010PCR, PFGE, Sequencing and MBL Etest strips\[[@CR25]\]Kenya1904423.2--*K. pneumoniae*2002--2013Disk diffusion\[[@CR26]\]Kenya1952512.8NDM-1 like*K. pneumoniae*1994--2017WGS\[[@CR27]\]Kenya17/2191/219 or 1/170.5/5.9--*K. pneumoniae*2010Disk diffusion\[[@CR28]\]Kenya4237--*E. coli*--Disk diffusion\[[@CR29]\]Uganda1964422.4OXA-48, IMP, KPC and NDM-1*K. pneumoniae. E. coli, Enterobacter* spp, *Serratia marcescens, Proteus mirabilis, Citrobacter freundii, Klebsiella oxytoca* and *Pantoea agglomerans*Jan 2013--Mar 2014PCR. Disk diffusion and Modified Hodge test\[[@CR30]\]Uganda6586810.3VIM and OXA-48*E. coli, K. pneumoniae, Proteus mirabilis, Salmonella* spp, *Morganella morganii, Enterobacter sakazaki* and *Stenotrophomonas* sppSept 2013--Jun 2014PCR and disk diffusion\[[@CR31]\]Uganda869 (clinical)101.2 (10/869)\
24 (10/42)IMP-like, VIM-like, SPM-like and NDM-1-like*P. aeruginosa* (42/658 = 5%)Feb 2007--Sep 2009PCR\
Phoenix Automated\
Microbiology System\[[@CR32]\]91.1 (9/869)\
31 (9/29)OXA-23,24, 58 like and VIM-like*A. baumannii* (29/658 = 3%)80 (environmental)1518.8 (15/80)\
33 (15/46)IMP-like, VIM-like, SPM-like and NDM-1-like*P. aeruginosa* 57.5% (46/80)67.5 (6/80)\
55 (6/11)OXA-23,24, 58 like and VIM-like*A. baumannii* 14% (11/80)Uganda736 (clinical)30.41 (3/736)\
33 (3/9)--*P. aeruginosa* (9/736 = 1.2%)Sept 2012--Oct 2013Rep-PCR and disk diffusion\[[@CR33]\]10.14 (1/736)\
14 (1/7)--*A. baumannii* (7/736 = 0.95%)100 (environmental)77 (7/100)\
21 (7/33)--*P. aeruginosa* (33/100 = 33%)66 (6/100)\
46 (6/13)--*A. baumannii* (13/100 = 13%)Tanzania9088.9VIM-2*P. aeruginosa*May 2010--Jul 2011Sequencing, PGFE and Disc diffusing\[[@CR34]\]Tanzania2278035VIM-, IMP-, NDM-KPC, OXA48*K. pneumoniae, P. aeruginosa, E. coli, K. oxytoca A. baumannii, Citrobacter freundii, Serratia marcescens* and *Salmonella* spp2007--2012PCR and disk diffusion\[[@CR35]\]Rwanda55/1545 in 154 or 5/552.9/8--*E. coli*Jul--Dec 2013Disk diffusion\[[@CR36]\]Ethiopia33412.1--*K. pneumoniae* and *Morganella morgani*Jan--Mar 2014Disc diffusion and\
Modified Hodge test\[[@CR37]\]Ethiopia26751.87--*K. pneumoniae*\
*E. coli*Dec 2012\[[@CR38]\]DRC104/6431 in 643 or 1/1040.2/0.96--*Enterobacter* spp.Sept 2012--Aug 2013Disk diffusion\[[@CR39]\]

### Data analysis {#Sec7}

Data analysis was performed using one-way ANOVA in XLSTAT version 2018.1 to establish the most prevalent carbapenem resistant bacteria type and their distribution variability within body systems. A *P* value of ≤ 0.05 indicated significant statistical difference.

Results {#Sec8}
-------

The search conducted between January and December 2017 generated 223 research articles; PubMed, Sciencedirect and African Journals Online liberated 27, 48 and 148 respectively. Using article abstracts and titles, 201 articles were excluded from this systematic review. Only 20 full text articles were accessible out of the 22 papers. Of the remaining 20 manuscripts, 17 presented concrete information about molecular epidemiology of CR in East Africa and consequently included in this review, Fig. [1](#Fig1){ref-type="fig"}. The search generated four manuscripts from Uganda, seven from Kenya, two from Ethiopia, and Tanzania, one from DRC and Rwanda, Table [1](#Tab1){ref-type="table"}. Neither articles from Burundi nor from South Sudan met inclusion criteria for this systematic review. All studies were epidemiological hospital based cross sectional in nature and majority illustrated the prevalence and genetic determinants of CR as well as the methods employed to detect CP isolates, Table [1](#Tab1){ref-type="table"}.

### Resistance patterns {#Sec9}

#### Clinical isolates {#Sec10}

According to the molecular and antibiotics susceptibility assays employed in the articles incorporated into this systematic review, Tanzania exhibited the highest level of CR among enteric clinical isolates at 35% while DRC had the lowest level at 0.96% \[[@CR35], [@CR38]\], Table [1](#Tab1){ref-type="table"}.

#### Hospital environment isolates {#Sec11}

Uganda was the only regional country with two studies documenting CR obtained amongst hospital environment isolates \[[@CR32], [@CR33]\]. These studies reported hospital environment CR prevalence ranging from 21% in *P. aeruginosa* to 55% in *A. baumannii,* Table [1](#Tab1){ref-type="table"}.

#### Body system harboring CP isolates {#Sec12}

Only 12 articles analyzed in this review had detailed information about the samples from which CP bacteria were isolated, Table [2](#Tab2){ref-type="table"}. The mean sample wise CP bacteria distribution was highest in respiratory tract samples (23%), followed by blood (22%), urine (19%), wound/pus (18%), stool and peritoneol fluid (10%), other samples (7%), ear swabs (6%) and cerebral fluid (3%), Additional file [1](#MOESM1){ref-type="media"}: Table S1. Seven studies reported CR in urine and blood isolates with prevalence ranging from 0.96% (DCR) to 39.2% (Tanzania) and 7% (Kenya) to 36.36% (Tanzania) respectively. Six articles documented respiratory tract CP bacteria with occurrence varying from 3.45% (Uganda) to 55.6% (Kenya) while five articles displayed CR in pus/wound isolates with a resistance incidence ranging from 7.14% (Uganda) to 33.04% (Tanzania), Table [2](#Tab2){ref-type="table"}.Table 2Sample wise distribution of CR bacteria isolatesCountrySample sourceCR prevalenceSpeciesRefsKenyaUrine\
Blood\
Wounds\
Respiratory tract specimens various other specimens3/57 = 5% (urine)\
4/57 = 7% (blood)\
17/57 = 30% (wound/pus)\
30/47 = 53% (respiratory)\
3/57 = 5% (various other specimens)*P. aeruginosa*\[[@CR22]\]KenyaBlood (190)44/190 = 23.2%*K. pneumoniae*\[[@CR24]\]KenyaRespiratory tract specimens\
Bone marrow aspirate cerebrospinal fluid\
Catheter tip\
Axillary swab\
Nasal swab\
Urine\
Blood\
Debrided tissue samples10/16 = 55.6% (respiratory)\
--\
--\
--\
--\
--\
--\
--\
--*A. baumanii*\[[@CR25]\]KenyaBlood (195)25/195 = 12.8%*K. pneumoniae*\[[@CR27]\]KenyaUrine (121)1/17 = 5.9%*K. pneumoniae*\[[@CR28]\]UgandaUrine\
Blood\
Stool\
Wound/pus\
Peritoneol fluid\
Others23%\
27%\
18%\
14%\
10%\
8%*E. coli, K. pneumoniae, Proteus mirabilis, Salmonella* spp, *Morganella morganii, Enterobacter sakazaki* and *Stenotrophomonas* spp\[[@CR31]\]UgandaBlood (51), cerebral spinal fluid (49), Tracheal aspirates (163), Ear swabs (197), Sputum (204), Urine catheters (98) and Pus (107)3/42 = 7.14% (wound/Pus)\
3/42 = 7.14% (Sputum)\
3/42 = 7.14% (Tracheal)\
1/42 = 2.4% (Ear swab)*P. aeruginose*\[[@CR32]\]4/29 = 13.8% (Tracheal)\
3/29 = 10.35% (Ear swap)\
1/29 = 3.45% (Sputum)\
1/29 = 3.45% (Cerebral Spinal fluid)*A. baumanii*TanzaniaBlood and pus5/90 = 5.6% Wound/Pus\
3/90 = 3.3% Blood*P. aeruginose*\[[@CR34]\]TanzaniaPus (112), urine (56), blood (55), aspirate (3), and sputum (1).22/56 = 39.29% (Urine)\
20/55 = 36.36% (Blood)\
37/112 = 33.04% (wound/Pus)*K. pneumoniae, P. aeruginosa, E. coli, K. oxytoca A. baumannii, Citrobacter*\
*freundii, Serratia marcescens* and *Salmonella* spp\[[@CR35]\]EthiopiaUrine (24)\
Blood (9)4/24 = 17% (urine)\
0/9 = 0% (blood)*K. pneumoniae* and *Morganella morgani*\[[@CR37]\]EthiopiaFeces (267)5/267 = 2% (feces)*K. pneumoniae*\
*E. coli*\[[@CR38]\]DRCUrine (104)1/104 = 0.96% (urine)*Enterobacter* spp\[[@CR39]\]

#### Distribution of CR among MDR enteric bacteria {#Sec13}

One-way ANOVA displayed that distribution of CR among different bacteria species was not significantly different (P-value = 0.11 \> 0.05). CR prevalence was highest in *A. baumannii* with an average of 23% followed by *P. aeruginosa* (17*%*), *K. pneumonia* (15%), *P. mirabili* (14%), *E. coli* (12%), *C. freundii* (8%), *K. oxytoca* (2%), *M. morganii* (2%), *Salmonella* spp *E. sakazaki* and *Stenotrophomonas* spp (1%). However, the most reported CP isolate across the region was *K. pneumoniae* (8 studies) followed by *E. coli* and *P. aeruginosa* (6 studies), *A. baumannii* (4 articles), *M. morganii* and *Salmonella* spp (2 articles)*, C. freundii*, *K. oxytoca* and *P. mirabilis* (2 articles), *E. sakazaki* and *Stenotrophomonas* spp (1 article), Additional file [1](#MOESM1){ref-type="media"}: Table S2.

### Prevalence of CR genetic determinants in East Africa {#Sec14}

#### Uganda {#Sec15}

CR genetic determinants in non-glucose fermenting bacteria reported at Mulago hospital were *bla*IMP-like (36%), *bla*VIM-like (32%), *bla*SPM-like (16%), *bla*NDM-1-like (4%) for *P. aeruginosa* and *bla*OXA-23-like (60%), *bla*OXA-24-like (7%), *bla*OXA-58-like (13%), and *bla*VIM-like (13%) for *A. baumannii* \[[@CR32]\]. Carbapenemase genes in CRE at Mulago and Mbarara hospitals were also documented \[[@CR30], [@CR31]\]. At Mulago, the genes characterized included; blaVIM (10.7%), followed by blaOXA-48 (9.7%), blaIMP (6.1%), blaKPC (5.1%) and blaNDM-1 (2.6%). The highest number of genes appeared in *Klebsiella pneumoniae* (52.2%), followed by *E. coli* (28.4%), *Enterobacter* spp (7.5%), *Serratia marcescens* (4.5%), *Proteus mirabilis* (3.0%), *Citrobacter freundii, Klebsiella oxytoca*, and *Pantoea agglomerans* at 1.5% each while at Mbarara hospital, VIM and OXA-48 CR determinants were registered, Table [1](#Tab1){ref-type="table"}.

#### Tanzania {#Sec16}

Molecular analysis of CRE at a tertiary hospital in Mwanza established by multiplex PCR revealed that the principal CR genes were IMP (21.6%), followed by VIM (12.3%), OXA-48 (4.9%), then KPC (3.5%), and NDM (3.1%). CP *E. coli* had the highest prevalence (14%), followed by *K. pneumoniae* (10.57%), trailed by *P. aeruginosa* (10.13%), then *Klebsiella oxytoca* (1.76%), *A. baumannii* (1.3%), *C. freundii* (0.88%), *Serratia marcescens* (0.88%) and *Salmonella* spp. (0.44%) \[[@CR35]\] while CP *P. aeruginosa* harbouring VIM CR gene were identified from Muhimbili National Hospital, using PCR \[[@CR34]\], Table [1](#Tab1){ref-type="table"}.

#### Kenya {#Sec17}

CP *K. pneumoniae*, *A. baumannii* and *Pseudomonas aeruginosa* possessing NDM and VIM-2 genes respectively were isolated in Nairobi \[[@CR21], [@CR24], [@CR25]\] while Whole Genome sequencing (WGS) was employed to identify NDM-1like CR genes in *K. pneumoniae* isolates at Kilifi County Hospital \[[@CR27]\], Table [1](#Tab1){ref-type="table"}.

Discussion {#Sec18}
----------

### Geographical prevalence of CP bacteria {#Sec19}

The most prevalent CRE across the region were *K. pneumoniae* and *E. coli*. CR in *K. pneumoniae* was reported by eight articles with mean prevalence of 15% in all East African countries except Rwanda and DRC while CP *E. coli* was accounted for in all countries apart from DCR by six studies with an average occurrence of 12%. This is in agreement with global data about CR. For example in USA, 11% of *K. pneumoniae* infections and 2% of *E. coli* infections were resistant to carbapenems \[[@CR40]\] while in India, 13% of *E. coli* infections and 57% of *K. pneumonia* infections were caused by CP strains \[[@CR41]\]. Additionally, high frequency of CR among the non-glucose fermenting *P. aeruginosa* (17%) and *A. baumannii* (23%) almost equal to that of CRE was registered in the region (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). This is in conformity with worldwide reports acknowledging that the magnitude of CP *A. baumannii* and *P. aeruginosa* is equal to that of CRE \[[@CR40]\].

### Prevalence of CR {#Sec20}

The highest frequency of CR in the region was 35%. This prevalence correlates with other studies in India \[[@CR43], [@CR44]\] where the prevalence was 43% and 30% respectively. Contrary, this frequency is higher than CR levels reported by other studies in Nigeria (15.2%) and USA (4.5%) but lower than that of 68% reported by a broad study executed in 7 out of the 9 provinces of South Africa \[[@CR45]--[@CR47]\].

### Carbapenem resistant bacteria in the hospital environment {#Sec21}

The actual occurrence of environmental contamination by CP bacteria is not well researched yet hospital environments tainted with CP bacteria by infected patients are implicated as the main routes of transmission \[[@CR48], [@CR49]\]. Across East Africa, only two studies conducted in Uganda reported the existence of CP *P. aeruginosa* and *A. baumannii* isolated from hospital environment. The frequency varied from 21% in *P. aeruginosa* to 55% in *A. baumannii,* Table [1](#Tab1){ref-type="table"}. Related studies which recovered CP bacteria from hospital environments in Israel and Brazil reported closely related results \[[@CR50]--[@CR52]\]. Horizontal transfer of mobile genetic elements from clinical pathogens to environmental bacteria can occur within the hospital environment hence promoting emergence of new resistant bacteria strains. Furthermore, resistant bacteria in hospital environment such as sewage may spill into the food chain, hence becoming one of the sources of community-acquired resistant pathogens \[[@CR40]\].

### Sample wise distribution of CP bacteria {#Sec22}

This systematic review revealed that CP bacteria are highly distributed in the respiratory tract (23%), Blood (22%), urinary tract (19%) and wounds/pus (18%) in East Africa and this is in line with other investigations conducted in India \[[@CR44], [@CR53]\] and USA \[[@CR46]\], where they reported high incidences of CR respiratory tract, urinary tract, blood and wound bacterial infections.

### CR knowledge gap in East Africa {#Sec23}

Various studies around the global have characterized the different variants of each genetic determinant of CR, Additional file [2](#MOESM2){ref-type="media"}: Tables S3--S5. Unfortunately, all these variants and their epidemiology are yet to be documented in East Africa, S-CRKGEA. Emergence of CR in *K. pneumonia* strains harbouring Extended Spectrum Beta-Lactamases-ESBLS (CTX-Ms or SHV-2) or plasmid borne AmpC enzymes (ACT-1, CMY-2, CMY-4 or DHA-1) in association to loss of outer membrane proteins (OMPs) as a result of truncated OMP gene \[[@CR54], [@CR55]\] is yet to be acknowledged in East Africa. Occurrence of CP bacteria in livestock and their environment was reported in Europe \[[@CR9]--[@CR12]\] while in East Africa no such research has ever been conducted.

Conclusion and recommendation {#Sec24}
=============================

Identification of CP bacterial infections at their first appearance provides an opportunity to interfere before these CP organisms are spread more extensively \[[@CR6]\]. Therefore, utilizing a robust molecular platform, the WGS, all genetic determinants of CR in humans, livestock and environment should be identified and documented hence bridging the knowledge gap about the molecular epidemiology of CP bacteria in East Africa. Antibiotics resistance stewardship team may profit from data generated by molecular testing of MDR organisms to enhance prevention of intra and inter health facility transmission and the possible cyclic transmission between livestock, humans and environment.

Limitations {#Sec25}
===========

Results of the 17 articles that illustrated significant CR across East Africa have been summarized by this review. However, in South Sudan and Burundi no studies have ever been conducted to investigate the epidemiology of CR. Furthermore, studies carried out in Rwanda, DRC, and Ethiopia were aimed at addressing general antimicrobial resistance hence providing very limited CR data while in Kenya, Uganda and Tanzania, more elaborate specific CR in enteric bacteria studies have be performed. Therefore this has led to a significant variation in knowledge about CR in the region.

Additional files
================

 {#Sec26}

**Additional file 1.** One way ANOVA results. **Table S1.** Mean percentage of sample wise distribution of carbapenem resistant isolates generated by One-Way ANOVA. **Table S2.** Average percentage prevalence of the different carbapenem resistant bacteria computed by One-Way ANOVA. **Additional file 2.** Class A, Class B and Class D genetic determinants of Carbapenem resistance. a. **Table S3**. Showing Ambler class A carbapenemase, their variants, organisms harbouring them and location. b. **Table S4.** MBLs, their variants, organisms harbouring them and location. c. **Table S5.** Carbapenem-hydrolyzing class D β-lactamases (CHDL), organisms harbouring them, their geographic distribution and location. d. **Table S6.** Shows the prevalence of carbapenem resistance in K. pneumonia in all WHO regions. e. Carbapenem resistance Knowledge gap in East Africa (S-CRKGEA).
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